Pipeline
Azalla Pharmaceuticals is currently investigating several programs for the potential treatment of collagen induced arthritis (CIA) and Crohn’s Disease (IBD).
The company’s lead candidates J-041 and J-019 are novel small molecule candidates currently in Preclinical development with plans to start Preclinical development for other indications soon.
